The existing vaccines are working against the dangerous Omicron, research shows

The protection of BioNTech / Pfizer vaccine cells by Johnson & Johnson Covid-19 is effective against the Omicron coronavirus, according to research, showing that the vaccine can protect against serious infections even if the antibody response is weak or strong. .

The findings, contained in a new study by Harvard Medical School, add to the evidence that current vaccines counteract the negative effects of Covid, and could help health officials decide to change the jabs following Omicron.

“These data suggest that modern vaccines may provide adequate protection against toxic diseases with Sars-Cov-2 Omicron strains despite significant reductions in antibody-response responses,” the researchers wrote. in the lesson was announced Monday. This paper has not been reviewed by peers.

Previous evidence suggests that the current vaccine loses its antibody potential against Omicron, meaning that people are less likely to become infected with the virus and less susceptible to infections.

The third shot slightly restores antibody protection, and countries have been rushing to expand their programs to avoid new bans. But vaccines are still expected to protect us from the deadly virus, and health officials will re-examine the evidence as found in Monday’s study to determine if switch to Omicron vaccine it is important.

Cell protection is a different part of the immune system that tends to last longer than antibodies.

As the 2022 production demonstrations show attendance will continue and the need in most cases if the country continues to use the current shot, switching to the Omicron vaccine could see a global spread.

Healthcare company Airfinity has decided – in the best case scenario – if all drug manufacturers change production and speed up, the 6bn Omicron shot will be available in October 2022. If drug manufacturers change half of their production and continue production. All versions, a target that would not arrive in January next year.

Health officials warned of the mutant version of the Omicron late last year, saying it could have been punctured because of immunity provided by previous vaccines or vaccines, but scientists believe the more commonly used shot can protect against dangerous diseases.

Previous findings suggest that Omicron appears to be smaller than the older species, but it is still unclear whether this is due to the same differences, or because many in the world are infected or vaccinated, or a combination of the two.

However, scientists have suggested that its widespread transmission, combined with an unrelated vaccine, could still affect health systems around the world. come under pressure when many people are sick.

The World Health Organization has repeatedly called for a fair distribution of the vaccine. It set a target of 70 percent in all countries by mid-2022 after nearly half of its member states failed to reach 40 percent in 2021. The health council said the failure to meet those targets was due to significant shortages. .